Literature DB >> 11606375

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

A J Philp1, I G Campbell, C Leet, E Vincan, S P Rockman, R H Whitehead, R J Thomas, W A Phillips.   

Abstract

Phosphatidylinositol 3'-kinases (PI3ks) are a family of lipid kinases that play a crucial role in a wide range of important cellular processes associated with malignant behavior including cell growth, migration, and survival. We have used single-strand conformational polymorphism/heteroduplex analysis to demonstrate the presence of somatic mutations in the gene for the p85alpha regulatory subunit of PI3k (PIK3R1) in primary human colon and ovarian tumors and cancer cell lines. All of the mutations lead to deletions in the inter-SH2 region of the molecule proximal to the serine608 autoregulatory site. Expression of a mutant protein with a 23 amino acid deletion leads to constitutive activation of PI3k providing the first direct evidence that p85alpha is a new oncogene involved in human tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606375

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  169 in total

1.  Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors:  Li-E Wang; Hongxia Ma; Katherine S Hale; Ming Yin; Larissa A Meyer; Hongliang Liu; Jie Li; Karen H Lu; Bryan T Hennessy; Xuesong Li; Margaret R Spitz; Qingyi Wei; Gordon B Mills
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-07       Impact factor: 4.553

2.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

3.  Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Authors:  Meng Chen; Jian Gu; George L Delclos; Ann M Killary; Zhen Fan; Michelle A T Hildebrandt; Robert M Chamberlain; H Barton Grossman; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

4.  Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo.

Authors:  Lazaros C Foukas; Caroline A Beeton; Jorgen Jensen; Wayne A Phillips; Peter R Shepherd
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

5.  The iSH2 domain of PI 3-kinase is a rigid tether for p110 and not a conformational switch.

Authors:  Zheng Fu; Eliah Aronoff-Spencer; Haiyan Wu; Gary J Gerfen; Jonathan M Backer
Journal:  Arch Biochem Biophys       Date:  2004-12-15       Impact factor: 4.013

6.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

Review 7.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 8.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

Review 9.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

10.  miR-486-5p regulates the migration and invasion of colorectal cancer cells through targeting PIK3R1.

Authors:  Yuhao Zhang; Jun Fu; Zhijin Zhang; Huanlong Qin
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.